Eden Bio

Executive Summary

Eden Bio, a UK-based biotechnology company founded in 2021, is pioneering an AI-driven platform, Eden Genetics, to optimize the genetic engineering of microorganisms for enhanced protein yield. The company targets scalable protein production for food, pharmaceuticals, and biofuels via precision fermentation. By leveraging machine learning, Eden Bio aims to address inefficiencies in biological manufacturing, supporting a more sustainable future. As a private, early-stage company with no disclosed funding or revenue, it represents a high-risk, high-reward opportunity in the synthetic biology space. Its conviction score of 55 reflects promising technology but lack of commercial validation.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Partnership with a Major Food or Pharma Company40% success
• Q2 2026Publication of Proof-of-Concept Data in Peer-Reviewed Journal70% success